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Defined factors to reactivate 
cell cycle activity in adult mouse 
cardiomyocytes
Justin Judd1, Jonathan Lovas1 & Guo N. Huang1,2,3*
Adult mammalian cardiomyocytes exit the cell cycle during the neonatal period, commensurate with 
the loss of regenerative capacity in adult mammalian hearts. We established conditions for long-term 
culture of adult mouse cardiomyocytes that are genetically labeled with fluorescence. This technique 
permits reliable analyses of proliferation of pre-existing cardiomyocytes without complications from 
cardiomyocyte marker expression loss due to dedifferentiation or significant contribution from cardiac 
progenitor cell expansion and differentiation in culture. Using this system, we took a candidate gene 
approach to screen for fetal-specific proliferative gene programs that can induce proliferation of adult 
mouse cardiomyocytes. Using pooled gene delivery and subtractive gene elimination, we identified a 
novel functional interaction between E2f Transcription Factor 2 (E2f2) and Brain Expressed X-Linked 
(Bex)/Transcription elongation factor A-like (Tceal) superfamily members Bex1 and Tceal8. Specifically, 
Bex1 and Tceal8 both preserved cell viability during E2f2-induced cell cycle re-entry. Although Tceal8 
inhibited E2f2-induced S-phase re-entry, Bex1 facilitated DNA synthesis while inhibiting cell death. In 
sum, our study provides a valuable method for adult cardiomyocyte proliferation research and suggests 
that Bex family proteins may function in modulating cell proliferation and death decisions during 
cardiomyocyte development and maturation.
Human and mouse cardiomyocytes (CMs) undergo endoreplication shortly after birth followed by cell cycle 
exit, resulting in mostly polyploid mature cardiomyocytes1–5. Neither species exhibits significant proliferation of 
cardiomyocytes in adulthood, potentially explaining why adult mammalian hearts do not regenerate. Neonatal 
mice (before postnatal day 7) and lower vertebrates (through adulthood) have demonstrated robust heart regen-
eration, due to the dedifferentiation and proliferation of pre-existing differentiated cardiomyocytes6,7. However, 
as mouse cardiomyocytes undergo maturation in the neonatal period, they lose the ability to proliferate and so 
does the adult mammalian heart lose the ability to regenerate6. Indeed, the rarity of myocardial-derived cancers8,9 
is consonant with the lack of proliferative potential of adult mammalian cardiomyocytes. Thus, the mechanism of 
permanent cell cycle exit and the potential for induced proliferation of mature mammalian cardiomyocytes has 
been a topic of intense investigation10–13 with potential for therapeutic intervention in cardiac diseases involving 
loss of cardiomyocytes.
Several articles in the last decade have reported increased cell cycle activity through the overexpression or 
suppression of various purported regulators of the cardiomyocyte cell cycle, reviewed elsewhere14–18. Suppression 
of the Hippo pathway with constitutively active Yap1 increased cardiomyocyte proliferation without increasing 
cardiomyocyte size10, and improved heart function after myocardial infarction19. Later work showed Yap inter-
acts with Pitx2 to upregulate antioxidants, which improved recovery after heart injury20. Still, the complex role 
of Hippo signaling is unraveling, and has been implicated in cardiomyocyte survival, as well as cardiac tissue 
remodeling and hypertrophic adaptation in heart failure21–23. Tbx20 overexpression in vivo increased cardiomy-
ocyte proliferation and reduced expression of senescence marker p16Ink4a, one of two proteins (the other being 
p19ARF/p14ARF in mice/humans, respectively) encoded by the Cdkn2A locus. Recently, Tbx6 was identified 
as a single factor that could increase cell cycle activity in postnatal and adult rat cardiomyocytes24. Silencing of a 
long non-coding RNA, cardiomyocyte proliferation regulator (CPR)25, or suppression of miRNA 12826 was found 
to increase cardiomyocyte cell cycle activity and help restore function after myocardial injury. Amazingly, four 
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factors (Cdk1, Cdk4, Cyclin B1, Cyclin D1) were sufficient to drive post-mitotic cardiomyocytes through cytoki-
nesis and improve myocardial function post-infarction27. Downregulation of Meis1 was shown to increase cardi-
omyocyte proliferation and was later found to play a role in the switch from glycolytic to oxidative metabolism28, 
a key event in the maturation of cardiomyocytes driven in large part by thyroid signaling29.
Collectively, there seem to be many potential proteins that can stimulate re-entry of CMs into the cell cycle. In 
this work, we used an in vitro screen to identify novel factors that can contribute to CM proliferation. However, 
the study of cardiomyocyte proliferation in vitro using fixed cell imaging is limited when the cells of interest 
dedifferentiate and lose marker identification. Wang et al. developed an adult mouse cardiomyocyte culture using 
lineage traced cardiomyocytes to demonstrate that adult mouse CMs require dedifferentiation in order to regain 
a proliferative phenotype30. CMs were shown to lose cardiac troponin I during dedifferentiation in vitro, but could 
be identified using a genetic fate mapped marker.
Here, we established a long-term adult mouse cardiomyocyte culture to enable genetic screening using 
well-characterized lineage tracing mouse genetics for facile identification of dedifferentiating cardiomyocytes. A 
candidate gene library was constructed by comparing novel microarray data from proliferative embryonic hearts 
and non-proliferative adult hearts. The candidate gene pool was further enriched for driver genes by selecting 
against genes downregulated in adult epicardium, and then supplemented with genes mined from published 
RNASeq and microarray data, creating the final candidate gene library. Each candidate gene was packaged into 
an adenovirus vector and delivered to cardiomyocytes en masse.
Cell cycle analysis by 5-ethynyl-2’-deoxyuridine (EdU) labeling revealed a high percentage of S-phase re-entry 
by overexpression of the entire pool of candidate genes. Subtractive pools identified known cell cycle protein 
E2f2 as sufficient for S-phase re-entry in cultured adult mouse cardiomyocytes. However, in contrast to previous 
work in neonatal mouse cardiomyocytes31,32, we found that overexpression of E2f2 caused massive cell death in 
adult mouse cardiomyocytes when cultured for several days after gene delivery. TUNEL staining showed elevated 
DNA nicking in E2f2-treated cultures, suggesting apoptosis may be partially responsible for cell death. Since the 
full pool of candidate genes did not cause widespread death, we then performed an additional screen to identify 
factors in the library that rescue cell viability. From this screen, we found two proteins from the Brain Expressed 
X-Linked (Bex)/Transcription elongation factor A-like (Tceal) superfamily, Tceal8 and BEX1, that rescue cell 
viability during E2f2 ectopic expression. Although both proteins rescued cell viability, Tceal8 inhibited S-phase 
re-entry in the presence of E2f2, while BEX1 allowed E2f2-induced S-phase re-entry. Therefore, this study impli-
cates Bex1 in the control of cell death decisions during cardiomyocyte replication and maturation.
Results
Adult mouse cardiomyocyte isolation and culture. We developed a long-term adult mouse cardiomy-
ocyte culture using well-characterized lineage tracing mouse genetics for facile identification of dedifferentiating 
cardiomyocytes. Cardiomyocytes were isolated from adult mice via retrograde perfusion and cultured in laminin-
coated 96 well plates. Lineage tracing mice, carrying the Tamoxifen inducible Cre, Tg(Myh6-mER-Cre-mER)33, 
and Rosa26CAG-LSL-tdTomato reporter alleles (Fig. 1a), were used to permanently mark cardiomyocytes in culture, 
enabling unambiguous identification despite morphological and/or transcriptional changes during dedifferentia-
tion. We found that cardiomyocytes isolated under these conditions can be cultured long term with high survival 
(Fig. 1b) (>50% after one week) and form networks that beat spontaneously and coordinately. Morphological 
dedifferentiation occurs during the first 3–5 days of culture, as the cells adjust to the 2-dimensional substrate by 
rounding, probably due to the absence of axial mechanical stimulation (Fig. 1b). The cardiomyocytes continue 
to adapt during the first couple weeks of culture, as they form new connections with other cardiomyocytes and 
reorganize their sarcomeres (Fig. 1b). Transduction by an adenovirus vector carrying a GFP reporter showed 
strong gene expression after 3 days (Fig. S1). Furthermore, similar to in vivo studies4,5, we found that adult mouse 
cardiomyocytes cultured in these conditions do not exhibit observable cell cycle activity (Fig. 2). Thus, this cul-
ture system is useful to screen for induction of proliferation by candidate genes using adenoviral vectors.
Candidate gene selection. It is well established that adult mammalian cardiomyocytes are highly resistant to 
cell cycle reactivation in physiological or pathological conditions. In contrast, the layer of epithelial cells that encap-
sulate the heart, or known as epicardial cells, are capable of cell division and rapid expansion in response to myocar-
dial injury34. Thus, we reasoned that master regulators of a proliferation-competent phenotype would still be active 
in epicardial cells, allowing them to re-enter the cell cycle in response to regenerative signaling. However, epicardial 
genes that are downregulated in adulthood are less likely to be master regulators required for cell cycle re-entry, and 
more likely are response genes that begin transcription downstream of activated master regulators.
Through gene expression comparison of epicardial and myocardial cells in both embryonic and adult hearts, 
we identified a list of candidate genes that are preferentially downregulated in the adult myocardium but not the 
adult epicardium (Table S1). Since our initial candidate genes contained novel factors with paralogs not repre-
sented by the microarray, such as those belonging to Bex/Tceal superfamily, we supplemented the gene pool with 
these additional genes. We also included 10 candidates based on reported functions in cardiomyocyte cell-cycle 
regulation, yielding a candidate gene list of 52 genes (Table S2). Due to low titers and difficulty of cloning, some 
genes were not included in the final pool of 36 candidate genes that were functionally tested (Table S3).
Candidate gene pool induces S-phase re-entry in adult mouse cardiomyocytes. Candidate genes 
were packaged individually into replication-defective serotype 5 adenoviral vectors. To determine if there exists 
a combination of genes in the candidate gene pool that can induce adult mouse cardiomyocyte proliferation, 
we combined all candidate gene vectors into a single pool and delivered to cardiomyocytes en masse at day 1 
post-isolation. S-phase re-entry was determined by labeling cardiomyocytes with EdU between days 2 and 7 
post-transduction. Staining revealed strong cell cycle induction (~17% EdU+ cardiomyocytes) from the pooled 
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candidate genes (Fig. 2a,b). We compared the effect of expressing the candidate gene pool to treatments that have 
been previously reported to stimulate cardiomyocyte proliferation. In our hands, combined treatment with FGF-1 
and p38 inhibitor did not result in strong EdU labeling of adult mouse cardiomyocytes (Fig. 2b). Constitutively 
active YapS112A (caYap) did induce cell cycle re-entry in adult cardiomyocytes, consistent with previous reports10,33 
A control adenoviral vector expressing GFP, similar to the untreated control, did not exhibit a significant effect 
on proliferative activity. In addition, staining of a cell cycle marker Ki67 showed a similar result with ~11% Ki67+ 
cardiomyocytes in the group transduced with the pooled viral vectors (Fig. S2).
Narrowing candidate genes to those sufficient for S-phase re-entry. To identify candidate genes 
sufficient for S-phase re-entry, we applied subtractive pools to the cardiomyocytes and labeled with EdU as before. 
First the total gene pool was divided, in no particular order, into two subpools, genes 1–17 and genes 18–36 
(Table S3). Delivery of these complementary subpools revealed subpool of genes 1–17, was significantly higher 
than the subpool of genes 18–36 pool for cell cycle induction (Fig. 2a), suggesting this subpool contains one or 
more candidate genes with strong cell cycle activity. This pool was further analyzed until a single virus trans-
gene, that overexpresses E2f2, was found to be sufficient to drive adult mouse cardiomyocyte EdU incorporation 
(Fig. 2d). Interestingly, E2f2 is down-regulated only by ~2 fold from E11.5 to adult epicardial cells but drastically 
by more than 20 folds from the E11.5 to adult myocardium (Table S2).
E2f2 is sufficient for S-phase re-entry, but induces cell death. E2f2 was previously reported to 
induce S-phase re-entry in cardiomyocytes32, thus we hypothesized this gene may be partially responsible for 
the cell cycle activity of the candidate gene pool. However, in contrast to previous reports31,32 we found that E2f2 
overexpression, in the absence of other candidate genes, induced massive cell death in adult mouse cardiomy-
ocytes under our culture conditions (Figs. 3 and S2). Both total cardiomyocyte counting (Fig. 3a) and longitu-
dinal tracking (Fig. 3b) revealed loss of more than 75% cardiomyocytes when E2f2 is overexpressed. TUNEL 
Figure 1. Live-cell imaging of genetically labeled adult mouse cardiomyocytes in culture. (a) Lineage-tracing 
transgenic mouse line was used to isolate adult cardiomyocytes, enabling unambiguous real-time identification 
during dedifferentiation. (b) Morphological changes of adult cardiomyocytes during dedifferentiation in vitro 
from day 1 (d1) to day 16 (d16). Cardiomyocytes are genetically marked by tdTomato before isolation and 
observed under the bright-field (top row) and fluorescent (bottom row) microscopy. Images of the same field 
are presented. Scale bar, 100 μm.
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staining was positive in many cells at 5 days post-transduction (Fig. S3). However, we did not observe TUNEL 
positive cardiomyocytes that were still positive for the tdTomato lineage marker. Due to the small percentage 
of non-cardiomyocytes, it was unlikely that all of the TUNEL positive cells are not cardiomyocytes. Thus, in 
E2f2-induced cardiomyocyte death, it seems that genomic degradation, detected by the TUNEL assay, likely 
occurred after cell membrane disruption.
Tceal8 and BEX1 rescue cell death. Since E2f2 did not appear to cause cell death when co-expressed with 
the rest of the candidate genes in the virus pool (Fig. S4), we performed an additional screen to identify factors 
that can preserve cell viability in the presence of E2f2 overexpression. To that end, we noticed that Subpool 1.2 
caused a similar degree of cardiomyocyte cell death to E2f2 alone (Fig. S4). Accordingly, we reasoned that one of 
the genes removed from Subpool 1.2 could rescue viability in the presence of E2f2. This Subpool lacked Tceal8, 
GOLM1, BMP4 and TUBB2B (Fig. S4). To test this, we co-expressed E2f2 with either Tceal8, GOLM1, BMP4, or 
TUBB2B, and then assessed cardiomyocyte viability at 7 days post-transduction (Fig. S5). Of these factors, only 
Tceal8 could rescue cell viability in the presence of E2f2 (Figs. 4a and S5). TUNEL staining confirmed a striking 
reduction of degraded genomic DNA (Fig. S6).
Since Tceal8 was effective at inhibiting cell death when co-expressed with E2f2, we suspected that other Bex/Tceal 
superfamily members may be able to regulate cell death in the context of E2f2 overexpression. To that end, we were 
able to clone other candidate genes belonging to the Bex/Tceal superfamily, Tceal5, Bex1, Bex3, and Bex4, and each 
was co-expressed with E2f2 (Fig. S5). Of these genes, Bex1 exhibited the strongest capacity to rescue E2f2-mediated 
cell death (Figs. 4a and S5). Western blot analysis of E2f2 showed that Tceal8 and BEX1 co-expression did not simply 
reduce E2f2 protein expression, but rather caused an increase in ectopic E2f2 protein accumulation (Fig. 4b).
Longitudinal imaging revealed that most E2f2-treated cardiomyocytes died between days 4 and 6 
post-transduction (Fig. 3b). By contrast, when co-expressed with BEX1, most E2f2-treated cardiomyocytes sur-
vived through day 8 post-transduction (Fig. 4c). Interestingly, co-expression with Tceal8 prevented cell death in 
E2f2-treated cardiomyocytes through at least 14 days post-transduction (Fig. 4d).
Figure 2. Candidate gene pool induces S-phase re-entry in cultured adult mouse cardiomyocytes. (a) Lineage-
traced cardiomyocytes transduced with a pool of candidate genes show S-phase activity via EdU labeling of 
in situ fixed cardiomyocytes. (b) Quantification of S-phase induction by pooled candidate genes compared 
to known cardiomyocyte cell cycle regulators p38i/FGF-1 and constitutively active Yap (caYap). Ad-GFP was 
used as a control for Adenovirus treatment. Negative control is no virus. (c) A subpool comprising genes 
1–17 contains a candidate gene that is capable of activation of EdU incorporation in adult cardiomyocytes. 
(d) Identification of E2F2 that is sufficient to induce adult cardiomyocyte S-phase entry. Error bars represent 
standard deviation of mean from greater than or equal to 3 independent experiments. Asterisk indicates 
significance p < 0.05 compared to negative control. Scale bars, 100 μm.
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Tceal8 suppresses but Bex1 permits E2f2-induced cell cycle re-entry. Surprisingly, assessment of 
DNA synthesis with EdU labeling showed that Tceal8 strongly inhibited E2f2-induced cell cycle re-entry (Fig. 5a). 
However, in contrast to Tceal8, BEX1 facilitated strong cell cycle re-entry when co-expressed with E2f2 in adult 
mouse cardiomyocytes (Fig. 5a). This proliferative activity was also verified by Ki67 staining: E2f2 and BEX1 
co-expression increases Ki67-positive cardiomyocytes to 27% (Fig. S7). We confirmed comparable expression 
levels of Tceal8 and BEX1 in our culture (Fig. S8). Altogether, these results suggest that Tceal8 and BEX1 have 
distinct functions in regulating E2f2-mediated gene transcription.
Real-time PCR showed that expression of an endogenous positive cell cycle regulator Cyclin E was induced by 
ectopic E2f2 expression, in agreement with its induction of S-phase (Fig. 5b). Tceal8 co-expression downregulated 
Cyclin E at the mRNA level, explaining the inhibitory effects of Tceal8 on cell cycle progression. Similar trends 
were observed for Cyclin A2 (Fig. 5b). In consonance with its permissive effect on DNA synthesis, BEX1 did not 
completely inhibit E2f2-mediated CyclinA2 and Cyclin E expression. Collectively, these data suggest that Tceal8 
may block cell cycle activity in part by inhibiting Cyclin expression.
BEX1 and Tceal8 expression is developmentally regulated in the heart. The observation that 
BEX1 rescues cell death while allowing cell cycle re-entry with E2f2 over-expression in adult cardiomyocytes is 
interesting and possibly relevant to the endogenous regulation of the cardiomyocyte cell cycle and maturation. 
Since murine cardiomyocytes are known to proliferate rapidly during early embryonic development, but perma-
nently exit the cell cycle shortly after birth, the mapping of Bex1 expression with respect to these cell cycle and 
maturation dynamics could lead to a better understanding of Bex1 function. Thus, to help understand the poten-
tial function of Bex1 in vivo, we searched available databases35 for the temporal dynamics of Bex1 expression in 
the developing heart. RNA-seq analyses showed high expression levels of Bex1 in the heart at E10.5, but a rapid 
reduction after birth (Fig. 6a). Interestingly, Tceal8 gene expression follows the same temporal trend (Fig. 6b). 
The drastic decreases of Bex1 and Tceal8 expression in the neonatal heart suggest that they may play important 
functions in cardiomyocyte cell-cycle exit and maturation in vivo.
Figure 3. E2F2 overexpression induces adult mouse cardiomyocyte (CM) cell death. (a) E2F2 was expressed 
by adenovirus vector at various multiplicity of infection (MOI). Cell viability is visualized by the transgenic 
tdTomato expression (red) at day 7 post-transduction and quantified on the right. (b) Longitudinal imaging of 
CMs revealed cell death in the E2F2-expressing group. Error bars represent standard deviation from duplicates 
in a single experiment. Scale bars, 100 μm.
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Discussion
Several reports have demonstrated increased cell cycle activity by ectopic gene expression in proliferative neonatal 
mammalian cardiomyocytes36–38, but fewer have shown cell cycle re-entry in adult mammalian cardiomyocytes. 
Of factors known to be sufficient for induction of DNA synthesis in adult mammalian cardiomyocytes, strong 
Figure 4. BEX1 and TCEAL8 delays or blocks E2F2-induced cell death in cultured adult mouse cardiomyocytes 
(CMs). (a) Cell viability is visualized by the transgenic tdTomato expression (red) in the field of view (FOV) at day 
7 post-transduction, and quantification plotted at right. (b) Western blot (top) and densitometric analysis (bottom) 
of ectopic V5-tagged E2F2 expression using an anti-V5 antibody. (c,d) Longitudinal imaging of tdTomato-labeled 
CMs when E2F2 was co-expressed with BEX1 (c) or TCEAL8 (d). Multiplicity of infection (MOI) is indicated in 
parentheses. *p < 0.05. Error bars represent standard deviation from 3 independent experiments. Scale bars, 100 μm.
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evidence exists for E2F transcription factors31,32, thus they are of interest to the pressing question of how adult 
mouse cardiomyocytes can be artificially stimulated to proliferate39,40. E2F transcription factors 1–3 are known 
activators of the cell cycle and are negatively regulated through sequestration by pocket proteins, such as retino-
blastoma protein (RB), p107, and p13041. Overexpression of E2F2 here by the CMV promoter likely overwhelms 
pocket protein sequestration of E2Fs, thus resulting in high levels of the activated free form E2F2, which upregu-
lated Cyclin expression and DNA synthesis31,32.
Expression of cell proliferation markers or incorporation of nucleotide analog in cardiomyocytes could lead 
to either cell division or cell hypertrophy. In our long-term culture system, we did not observe cardiomyocyte 
cytokinesis after E2f2 overexpression. Thus, it is possible that E2f2 could induce cardiomyocyte hypertrophy. 
Another possibility is that our in vitro system is not optimized for cardiomyocyte cytokinesis to occur because we 
did neither observe cardiomyocyte division when constitutively active Yap was overexpressed, which have been to 
promote cardiomyocyte division in vivo10. Thus, future works should determine if overexpression of E2f2 alone or 
together with Bex1 in the rodent heart induce cardiomyocyte proliferation or hypertrophy in vivo.
Long-term culture did not result in cytokinesis, rather all cells treated with Ad-E2f2 eventually died. The 
exact type of cell death is unclear, but may be related to several potentially overlapping and concurrent death pro-
cesses42. Notably, we observed positive TUNEL staining in Ad-E2f2-treated cardiomyocytes, but did not observe 
TUNEL positive cells that were also positive for the lineage tracing marker tdTomato. Previous work showed that 
Figure 5. BEX1 and TCEAL8 inhibit cell death while modulating S-phase re-entry. (a) BEX1 permits S-phase 
re-entry by E2F2, but TCEAL8 co-expression strongly inhibits DNA synthesis. (b) RT-PCR analysis of positive 
cell cycle regulator genes Ccne1 (Cyclin E) and Ccna2 (Cyclin A2). (c) RT-PCR analysis of cell apoptosis 
regulator genes Cdkn2a (p19ARF) and Cdkn1a (p21CIP). Error bars represent standard deviation of mean from 
three independent experiments. *p < 0.05, **p < 0.01.
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fluorescent protein expression is diminished in apoptotic cells, but that necrotic cells almost completely lose fluo-
rescent signal43. Thus, it appears that genomic degradation may have occurred after membrane permeabilization 
due to forms of cell death other than apoptosis, such as necrosis44–46. It should be noted that Bex1 has been shown 
to inhibit apoptosis in the rat central nervous system47. Although our data suggest a cellular death mechanism 
other than apoptosis (Fig S3), there may be common pathways involved in multiple forms of cell death48.
The primary cause of cell death could potentially be through dysregulation of E2f2 temporal dynamics or 
expression levels, leading to death signaling due to failed cell cycle checkpoints. In post-mitotic neurons, E2F 
activation can lead to cell cycle re-entry followed by cell death49. This phenomenon seems to be cell context 
dependent and may play a role in neurodegeneration50. Furthermore, E2f2 and E2F1 were reported to provide 
genomic stability in some neurons in the context of DNA damage51. This study additionally showed accumulation 
of E2f2 protein levels, despite unchanged transcription. This is especially interesting considering our observation 
that BEX1 and Tceal8 appear to also allow the accumulation of E2f2 protein, detected via western blot (Fig. 4b). 
Additionally, since E2f1 is also sequestered by Rb, it is possible that a significant proportion of endogenous E2f1 
is available in its activated form under these conditions, potentially contributing to observed cell death. Finally, 
during the first several days of culture, when gene delivery is taking place, the cells are only loosely attached. 
Thus, it is possible that delivery of viruses to CMs later in culture when they have adapted to culture conditions 
and are well-anchored may have a different effect. In future work, it would be interesting to test the effect of 
drug-inducible E2f2 expression at different time points in order to see if transient E2f2 expression can enable 
post-mitotic cardiomyocyte cell cycle re-entry without cell death.
The mechanism of rescue from cell death and cell cycle modulation by Bex1 and Tceal8 are unclear, but may 
be suggested by RT-PCR data (Fig. 5). Specifically, p21CIP152,53 and p19ARF54,55 are involved in cell cycle control 
and cell death decisions, and have even been reported to interact56,57. For example, p19-ARF, in addition to other 
functions, appears to induce apoptosis in response to E2F overexpression58. Since our data suggest non-apoptotic 
cell death, it is further interesting that a short form of p19ARF was reported to contribute to caspase-independent 
cell death59. P21, like p19, has also been shown to have multiple roles in coordinating the cell cycle with cell death 
decisions, and is additionally involved in thyroid-mediated cardiomyocyte maturation60. Moreover, p21 has been 
shown to oppose E2F signaling, which may explain why its expression was increased in response to damaging 
levels of E2f2 overexpression61. Since p19ARF is known to target E2F transcription factors for proteasomal deg-
radation49, it is also possible that accumulation of E2F2 by Bex1 and Tceal8 could be through suppression of 
p19ARF (Fig. 5). Furthermore, downregulation of p21 and p19, both having roles as cell cycle inhibitors, could 
potentially explain how BEX1 facilitates S-phase entry. Why Tceal8 does not facilitate S-phase re-entry under our 
conditions, despite downregulation of both p21 and p19, could be simply related to its stronger effect on Cyclin 
E downregulation. Furthermore, Tceal8 appeared to allow S-phase re-entry when co-delivered with Subpool 1, 
but not when only co-delivered with E2f2 (Figs. 2a, 5a); thus, there may be other factors in Subpool 1 responsible 
for the discrepancy.
The endogenous function of Bex/Tceal family proteins are largely unknown, but previous work has shown 
their role in other cell types such as neuronal differentiation62 and skeletal myoblast maturation63,64. BEX1 has 
been shown to regulate NGF signaling in neurons by altering its activity on p75NTR and trkA. The alteration in 
NGF signaling by BEX1 prevents downstream activation of NFkB and thereby prevents neuron differentiation. 
Furthermore, NGF has a prosurvival effect on rat cardiomyocytes65 and long-term NGF signaling may contribute 
to myocardial deterioration in chronic heart failure66. Here, it is tempting to speculate that Bex1 (and possibly 
Tceal8) may be involved in transducing death and differentiation signals in cardiomyocytes through p75NTR in 
concert with SC-1, as has been previously suggested67. In support of this hypothesis, SC-1 has been shown to 
inhibit cell cycle progression by repressing Cyclin E transcription68. A possible role for Bex1 here would be con-
sistent with our observation that Bex1 (or Tceal8) overexpression downregulates Cyclin E expression induced by 
E2f2. Thus, the p75NTR/SC-1 signaling axis may provide a mechanism for the ability of Bex1 to inhibit cell death. 
On the other hand, since our experiments relied solely upon Adenovirus-mediated gene delivery, it cannot be 
ruled out the possibility that phenotypes observed in this work are affected by virus-mediated signaling.
Figure 6. Bex1 and Tceal8 expression in mouse heart development. Data are derived from published RNA-seq 
data35. Error bars represent standard deviation (n = 3).
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Since Bex1 has been shown to interact with many different proteins, several potential mechanisms, inde-
pendent of p75NTR signaling, are suggested by previous work. For example, BEX1 has been reported to bind 
Calmodulin64, BAG4/SODD, and Caspase 869, all of which have roles in death signaling through DISC70–72. In 
contrast to our observations, Bex1 has been shown to have a pro-apoptotic role by binding to Bcl2 in cancer 
cells73. However, it is unclear what role the cellular context plays in determining the downstream outcome of this 
interaction. Bex family proteins have also been shown69,74 to interact with several common proteins - RAD51, 
ATM, AKT, AURKA, c-JUN, CHEK2 – as does BRCA1, which regulates DNA damage through the BASC com-
plex75, and is required for CCNE1 amplified tumors76. Alternatively, Bex1 interactor Pax269 has been shown to 
regulate retinoblastoma protein77, a particularly interesting observation given the role of RB in controlling E2F2 
activity. Moreover, BEX1 binds FBXW769, an F-box protein which promotes Cyclin E degradation through the 
SKP1-Cullin1-F-BOX (SCF) E3 ligase complex78. This interaction could help explain how Bex1 (and possibly 
Tceal8) reduces Cyclin E expression in response to ectopic E2f2. Furthermore, high Cyclin E levels have been 
shown to selectively degrade activator E2Fs79, potentially explaining why co-expression of Bex1 or Tceal8 actually 
increases E2f2 protein levels in contrast to Cyclin E suppression (Figs. 4 and 5). Finally, PTEN, may interact with 
Bex1, as well as several common interacting proteins, such as AKT, CASP8, FBXW7, STK11, FZR1, and MDFI80, 
and PTEN functionally interacts with p19ARF81, p21CIP82, and regulates cyclins83,84. Moreover, PTEN has been 
shown to be an effector of apoptosis inhibition by retinoic acid85. Thus, PTEN should be considered as a potential 
molecular player in Bex1 signaling in the context of cardiomyocyte maturation and survival.
In recent work, Bex1 was found to mediate pro-inflammatory signaling by selective modulation of AU-rich 
mRNA targets in a model of heart failure86. Thus, it is conceivable that Bex family-mediated RNA processing 
could play a role in shaping the cardiomyocyte response to E2f2-induced stress, but further investigation would 
be required. RNAseq data in rats from those experiments, deposited by Accornero et al., in contrast to our results, 
show that Bex1 overexpression actually increased Cyclin and cyclin-dependent kinase inhibitor (cdki) expres-
sion, including Cyclin E and p21CIP. Thus, it is unclear how the cellular context affects the action of Bex1 on cell 
cycle protein expression. For example, it is possible that Adenovirus signaling could play a role in shaping the 
response of CMs to both E2F2 and Bex1/Tceal8 overexpression. Alternatively, considering the mild phenotypes in 
Bex1 knockout animals, it is conceivable that Bex1, and possibly other Bex family proteins act to fine tune cyclin 
expression in order to modulate cell cycle and cell death decisions, thus explaining how Bex family proteins may 
be able to increase or decrease target transcript/protein expression depending on the cellular context.
Aside from the aforementioned potential mechanisms for Bex superfamily mediated regulation of cell death 
and proliferation, it is interesting to consider the Hippo pathway, due to its role in cardiac proliferation, regen-
eration, and cell death10,19–23 as well as its regulation via WW domain interactions87 and due to the interaction 
between Bex1 and the Hippo- and NFKB-interacting protein LMP188. YAP, a major signaling protein in the 
Hippo pathway, is known to interact with proteins via a WW domain by binding to proline rich recognition 
sequences89. Tceal9 (Wbp5) has been shown to induce Yap nuclear localization90, a sign of Yap activation. Since 
TCEAL9 contains a WW binding domain and TCEAL8 contains a proline rich sequence at its C-terminus, it is 
possible that other Bex/Tceal superfamily members may interact with Yap and play a role in the outcome of Hippo 
signaling91,92. Furthermore, miRNA signaling has been shown to control Tceal family proteins in the context of 
Yap signaling90.
It should be noted that the specific MOIs used in this study could have played a role in the differential effect 
between Bex1 and Tceal8, but in our hands lower MOIs of Bex1 had no effect and higher MOIs caused cellular 
toxicity (data not shown). Lower MOIs of Tceal8 did not allow S-phase re-entry while rescuing cell death. Thus, 
it appears the actions of Bex1 and Tceal8 on S-phase re-entry are distinct. It is also worth mentioning that the 
ectopically expressed BEX1 used in this experiment is of human origin, while E2f2 and Tceal8 are derived from 
mouse cDNA. Thus, it is possible that mouse Bex1 and human Bex1 could have different effects. It is also possible 
that Bex1 derived from mouse could have a similar effect at a lower MOI. Expression in Ad293 cells showed sim-
ilar protein levels between Bex1 and Tceal8 despite Ad-Bex1 being delivered at 40X higher MOI than Ad-Tceal8 
(Fig. S8). This could be due to differential silencing of the Bex1 transcript, inefficient translation, or protein 
degradation, distinct from Tceal8. It is also possible that the difference in gene function of Tceal8 and Bex1 could 
have affected the virus titer assay.
The interplay between death and differentiation signaling is becoming increasingly appreciated63,93–95. Our 
results showed that Bex1 is highly expressed in early stages of myocardial development and that Bex1 and Tceal8 
inhibited cell death in response to ectopic E2f2. Furthermore, Bex family proteins have been suggested to behave 
as disordered signaling hubs74, involving their interaction with many different protein partners. Collectively, 
these data and ideas suggest that Bex family proteins may act at several different levels to coordinate the balance 
between cellular decisions of death, division and differentiation during early stages of heart development and 
cardiomyocyte maturation.
Methods
RNA expression. Microarray analysis for candidate gene selection. In order to compare gene expression 
between the epicardium and myocardium in both adult and embryonic hearts, six groups of RNA were prepared:
 (1) E9.5 Tcf21LacZ proepicardial organ (PEO) lacZ-positive cells
 (2) E9.5 Tcf21LacZ proepicardial organ (PEO) lacZ-negative cells.
 (3) E11.5 Tcf21LacZ heart lacZ-positive cells.
 (4) E11.5 Tcf21LacZ heart lacZ-negative cells.
 (5) Adult epicardium-enriched cells.
 (6) Adult hearts.
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Tcf21 is a marker for embryonic epicardial cells96, thus in Tcf21LacZ mouse embryos, epicardial cells express 
the lacZ transgene.
To isolate epicardial cells from E9.5 and E11.5 Tcf21LacZ mouse embryos, CD-1 females were mated with 
Tcf21LacZ males and hearts were harvested from 25–40 E9.5 or E11.5 embryos. Cells were dissociated by try-
sinization at 37 °C for 20 minutes and resuspended in 100 μL prewarmed Leibovitz’s L15 medium (Invitrogen). 
Next, single cell suspensions were mixed with 100 μL prewarmed 2 mM fluorescein di-β-D-galactopyranoside 
(FDG) (Invitrogen) diluted in water and then incubated in a 37 °C water bath for 1–2 minutes to permit substrate 
uptake. Finally, 800 μL ice-cold L15 medium was added to the mixture and the cells were placed on ice for 30 to 
60 minutes before fluorescence activated cell sorting (FACS). Cells were sorted directly into Trizol solution for 
RNA extraction.
Because most adult epicardial cells don’t express Tcf21 any more, adult epicardium-enriched RNA was iso-
lated from the lysates after dissolving the surface (epicardial) cells of an entire adult ventricle from a 2-month old 
mouse in Trizol for 1 min. For adult heart, RNA was isolated from the entire adult ventricle from a 2-month old 
mouse.
RNA was extracted with the miRNeasy kit (Qiagen) following manufacturer’s instructions. For microarray 
analysis, 500 ng RNA and an Illumina mouse-6 gene chip were used.
Microarray data were obtained and analyzed by the Microarray Core facility of University of Texas 
Southwestern Medical Center.
RNA expression in vitro. RNA extraction was performed on cardiomyocyte cultures by Trizol (Invitrogen) fol-
lowing manufacturer’s instructions. Briefly, culture dishes were placed on ice, media was removed and Trizol 
added, followed by homogenization by repeated pipetting. RNA was then extracted by ethanol-stabilized chloro-
form (Acros Organics), supplemented with 5 ug glycogen (Invitrogen) co-precipitant and precipitated in 0.3 M 
sodium acetate, pH 5.5. Pellets were washed in 75% ethanol, followed by resuspension in RNAse-free water. 
cDNA was prepared using iScript Supermix (BIO-RAD) according to manufacturer’s instructions. qPCR was per-
formed on 7900 HT thermal cycler (Applied Biosystems) in 386 well plates using SYBR Select Master Mix (Life 
Technologies). RT-PCR primers are listed in Table S4. Changes in gene expression, compared to control samples, 
were calculated using ΔΔCt relative quantitation97.
Western blot. Protein samples were obtained by replacing cell culture medium with 1% sodium dodecyl 
sulfate containing 1X protease inhibitor cocktail (Sigma P8340). Separation was performed in 4–12% Bis-Tris 
NuPAGE gels (Invitrogen) in MES-SDS buffer (Invitrogen) under reducing conditions. Proteins were then trans-
ferred to PVDF-Plus membranes (Spectrum Chemical) and blocked in 5% milk in TBST (0.1% Tween 20). Blots 
were probed overnight at 4 deg C with rabbit anti-V5 (Cell Signaling Technologies; 1:1000 in 5% BSA, 0.1% Tween 
20, TBS) or for 1 hr at room temperature with mouse anti-β actin (GeneTex; 1:2000 in 1% BSA, 0.1% Tween 20, 
TBS), mouse anti-Bex1/2 or anti-E2f2 (Santa Cruz Biotech sc-376342 or sc-9967; 1:100 in 1% BSA, 0.1% Tween 
20, TBS) primary antibodies. Anti-mouse or -rabbit secondary antibodies (GE) were incubated in 5% milk in 
TBST for 1 hour at room temperature. Western lightning enhanced chemiluminescence substrate was applied and 
blots exposed to Hyblot CL film (Denville). Semi-quantitation of western blots was done in Fiji by subtracting 
background with a 50 um radius, followed by integrated intensity measurement.
Adenovirus vectors. Candidate gene cloning and virus production. Candidate gene ORFs were cloned into 
gateway entry vector pDONR-221 (Invitrogen) via PCR amplification with primers containing the attB recombi-
nation sequences. After sequence verification, entry vectors were recombined with the adenovirus type 5 destina-
tion vector pAd5-CMV-V5-DEST using LR Clonase (Invitrogen). pAd5 vectors carrying candidate gene vectors 
were further sequenced to confirm gene identity, and then digested with Pac I (NEB) for plasmid linearization. 
After phenol-chloroform extraction and ethanol precipitation, linearized plasmids were transfected into Ad293 
producer cells by polyethyleneimine complexation. Adenoviruses were harvested when a 50% cytopathic effect 
was observed. Cells were collected by cell scraping in culture media, followed by centrifugation at 1000 G × 5 min 
and concentration by removing all but 2 ml of media. Lysates were prepared by 4 freeze/thaws, cleared by centrif-
ugation and stored at −80 degC.
Virus titer. Virus titer was determined by infecting Ad293 cells with serial dilutions of virus lysate. Cytopathic 
effect was scored and the dilution at which isolated viral plaques were observed was used to determine the con-
centration of infectious units (IU). Vectors exhibiting titers less than 1e5 IU/ml were considered low titer and 
were not evaluated. Each multiplicity of infection (MOI) reported in this work refers to the number of virus IU 
(determined in Ad293) per cardiomyocyte. Thus, the effective MOI in cardiomyocytes may differ depending on 
the relative permissivity between Ad293 and cardiomyocytes.
Cardiomyocyte isolation and culture. Cardiomyocytes were isolated by retrograde perfusion of colla-
genase and protease XIV to digest extracellular matrix as previously described98. Cells were plated at approxi-
mately 15,000 cells/cm2 laminin (Corning) coated plasma-treated polystyrene in 96 well plates (Corning). Cells 
were cultured in Modified Eagle’s Medium (Corning) with 10% fetal bovine serum (JRS) and Primocin antibiotic 
(Invitrogen). Half-change of media was performed every 2–4 days. Cardiomyocytes were typically transduced by 
adding virus cell lysate on day 1 post-isolation. For viability assay, live cells were counted manually, as determined 
by the presence of positive tdTomato fluorescent signal.
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DNA synthesis. S-phase activity was detected by addition of EdU (Santa Cruz Biotechnology) to cell culture 
media between days 2–7 post-transduction. Staining was performed on formaldehyde fixed samples after per-
meabilization with 0.1% Triton X-100 and blocking with 3% bovine serum albumin (Santa Cruz Biotechnology) 
in phosphate-buffered saline. Briefly, staining solution (0.1 M ascorbic acid, 50 mM Tris-Cl, 1 mM CuSO4, pH 
7) containing 10 uM Sulfo-Cyanine5 azide dye (Lumiprobe) was applied for 10–20 minutes at room tempera-
ture, washed in PBS and followed by Hoescht 33342 (Gibco) nuclear counterstaining and several PBS washes. 
EdU+cells were counted manually in ImageJ using PointPicker.
Animal use. All procedures and experiments have been approved by the Institutional Animal Use and Care 
Committee at the University of California, San Francisco. All experiments and procedures were performed in 
accordance with relevant guidelines and regulations.
Statistics. For all counts used in statistical tests, including EdU+ cells and cell number counts, >100 total 
cells per sample (except for cells treated with E2f2 alone) were counted in ImageJ using PointPicker. For cell 
culture samples treated with E2f2 alone (not in combination with Bex1 or Tceal8), the large degree of cell death 
resulted in lower cell counts (~20–50 per sample). P-values were derived using one-sided Welch’s test in excel. 
For RT-PCR data normalized to negative controls (Fig. 5), statistical tests comparing to negative control were 
performed using a one-sided lower confidence interval for the mean of the treated group using the student’s 
t-distribution. RT-PCR data not comparing to negative controls were evaluated using the Welch’s test in excel.
Data availability
Further details of all data and methods are available upon request.
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